Targeting Astrocytes for Treatment in Amyotrophic Lateral Sclerosis

Author(s): Mina Peric , Dinko Mitrecic , Pavle R. Andjus* .

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 33 , 2017

Abstract:

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder affecting upper and lower motoneurons. The two types, sporadic and familial differ in the aetiopathogenesis but have a similar neuropathology characterized by oxidative stress, excitotoxicity and inflammation. The disease is also characterized by a non-cell autonomous mechanism with astrocytes playing a central role by affecting synaptic glutamate, the blood-brain barrier, and metabolic and trophic support. Two types of therapeutic approaches focusing on astrocytes are presented: a) emerging molecular targets (potassium inward rectifier channels and aquaporins at the astrocyte endfeet, and IP3 receptor signaling pathway), and b) cell therapy with stem cell - generated and transplanted astrocytes.

Keywords: Blood-brain barrier, astrocyte, endfeet, Kir4.1, AQP4, IP3 receptor pathway, stem cells, cell transplantation.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 23
ISSUE: 33
Year: 2017
Page: [5037 - 5044]
Pages: 8
DOI: 10.2174/1381612823666170615110446
Price: $58

Article Metrics

PDF: 38
HTML: 3
EPUB: 2
PRC: 7